ArticleInternational neurourology journal2026
Modulating Secondary Inflammation After Spinal Cord Injury Affects Pathological Bladder Remodeling.
Article in International neurourology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeNeurogenic lower urinary tract dysfunction (nLUTD) develops in nearly all patients after spinal cord injury (SCI). Evolving neuroinflammation is considered a key driver of secondary injury and is associated with worsening outcomes. However, few studies have examined treatments for nLUTD after SCI that specifically target these processes. This study investigated whether early montelukast therapy targeting proinflammatory leukotrienes improves long-term urological function and reduces pathological bladder remodeling.
methodsFemale Lewis rats received a permanently implanted urinary catheter and underwent contusion SCI (Th8/Th9) or sham surgery. Daily montelukast treatment began 1 day after injury and continued throughout the 2- or 6-month follow-up period. Injury severity and regeneration were evaluated using the Basso-Beattie-Bresnahan locomotor score and microcomputed tomography of the spinal cord. Bladder function was assessed through weekly urodynamic recordings in awake animals, and bladder structure was assessed by histological measurement of wall thickness. Transcriptomic and proteomic analyses were used to characterize the molecular processes underlying bladder remodeling.
resultsSpinal cord tissue damage and functional impairment were comparable across animals, regardless of treatment. Montelukast did not improve urodynamic outcomes and was associated with transiently poorer functional scores during early recovery. Bladder wall thickness increased after SCI and was greatest in the treated groups, suggesting ongoing remodeling. Transcriptomic and proteomic analyses demonstrated marked activation of immune and contractility-related pathways in treated animals at 2 months. Animals followed for the longer period showed intensified immune signaling, indicating sustained inflammatory activity.
conclusionEarly montelukast treatment did not improve functional or structural urological outcomes after contusion SCI. The unfavorable functional trends and intensified inflammatory and injury-related pathways suggested adverse effects rather than therapeutic benefit under the conditions studied. These findings may indicate the importance of injury model-specific mechanisms and of dose and timing when developing anti-inflammatory strategies for SCI-induced nLUTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.